eligibility_summary
Eligible: RRMM with measurable disease, ECOG 0–1. Prior therapy: Part 1 requires ≥3 regimens, Part 2 allows 1–3 or ≥3 per arm. Exclude prior use of alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D), BCMA‑targeted therapy for Part 2 Arms A/D, or any GPRC5D‑targeted therapy. Other protocol criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, open-label RRMM study of arlocabtagene autoleucel (BMS-986393, arlo-cel), an autologous anti‑GPRC5D CAR T-cell therapy, combined with: (A) alnuctamab (BMS-986349, CC‑93269), a BCMA×CD3 bispecific T‑cell–engaging antibody, (B) mezigdomide (BMS‑986348, CC‑92480), an oral CELMoD, (C) iberdomide (BMS‑986382, CC‑220), an oral CELMoD, (D) elranatamab (Elrexfio), a BCMA×CD3 bispecific antibody. Mechanisms/targets: arlo‑cel redirects autologous T cells to kill GPRC5D+ myeloma cells, alnuctamab/elranatamab link CD3 on T cells to BCMA on myeloma cells to induce T‑cell cytotoxicity, mezigdomide/iberdomide bind cereblon (CRBN) to degrade IKZF1/3, enhancing T/NK activation and suppressing myeloma survival pathways (e.g., IRF4/MYC). Aim: define safe/tolerable combination doses and prelim efficacy.